Article

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

2025-12-05

Abstract excerpt

Treatment of NSCLC KRAS G12C mutant tumors with the allele-selective sotorasib inhibitor is invariably associated with acquired resistance. The MUC1-encoded oncogenic M1C protein is necessary for self-renewal of NSCLC KRAS mutant cells. We report that treatment of NSCLC KRAS G12C cells with sotorasib induces M1C expression by a STAT1-dependent pathway. In turn, M1C drives sotorasib resistance by NF-κB-mediated ind...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1ffb21d5-c8e9-5102-8d7d-2a73088bc0fe
DOI: 10.64898/2025.12.02.691049

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitorsDOI 10.64898/2025.12.02.691049Read

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read

Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.Semantic proximity Read

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.Semantic proximity Read

Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.Semantic proximity Read

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.Semantic proximity Read

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.Semantic proximity Read

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancerSemantic proximity Read